1. Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis
- Author
-
I. Griffoul-Espitalier, Philippe Goupille, Nicolas Azzopardi, Gilles Paintaud, D. Chu Miow Lin, Denis Mulleman, Jean-Pierre Valat, Cambefort, Jeanne, Azzopardi, Nicolas, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Centre d’Investigation Clinique [Tours] CIC 1415 (CIC ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Tours-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Male ,Time Factors ,[SDV]Life Sciences [q-bio] ,030226 pharmacology & pharmacy ,Severity of Illness Index ,Cohort Studies ,0302 clinical medicine ,Immunology and Allergy ,Infusions, Intravenous ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,Antibodies, Monoclonal ,Long term maintenance ,General Medicine ,Middle Aged ,Response to treatment ,3. Good health ,Predictive factor ,[SDV] Life Sciences [q-bio] ,Treatment Outcome ,[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system ,Antirheumatic Agents ,Female ,[SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy ,medicine.drug ,musculoskeletal diseases ,Adult ,medicine.medical_specialty ,Immunology ,Trough (economics) ,Risk Assessment ,Drug Administration Schedule ,03 medical and health sciences ,[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,Rheumatology ,Predictive Value of Tests ,Internal medicine ,medicine ,Humans ,Spondylitis, Ankylosing ,Aged ,Monitoring, Physiologic ,030203 arthritis & rheumatology ,Ankylosing spondylitis ,Dose-Response Relationship, Drug ,business.industry ,[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy ,medicine.disease ,Long-Term Care ,Infliximab ,Surgery ,business ,Follow-Up Studies - Abstract
Infliximab is approved for refractory ankylosing spondylitis (AS) but 39% of patients experience no response to treatment after 24 weeks [1]. de Vries et al reported that the clinical response was ...
- Published
- 2010